← Back to Clinical Trials
Recruiting NCT06227468

A Clinical Study to Map the HLA Genomic Region in the Greek Population

Trial Parameters

Condition Healthy
Sponsor Athens LifeTech Park
Study Type OBSERVATIONAL
Phase N/A
Enrollment 12,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-12-12
Completion 2025-05-31

Brief Summary

The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.

Eligibility Criteria

Inclusion Criteria: The study will include adult subjects (age ≥ 18) that: * possess a Greek social security number and are visiting hospitals/clinics, and/or other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece, * are willing and able to provide written informed consent to participate in the study according to the study protocol. Exclusion Criteria: * Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity). * Subjects who have had an allogeneic (non-self-donor): * bone marrow transplant * stem cell transplant * blood transfusion less than two weeks prior to buccal swab sample collection * liver transplant * Subjects who participated in an interventional clinical trial in the past that according to the subject's physician opinion might have had an impact on their HLA genome.

Related Trials